Cardlytics Inc (NASDAQ:CDLX) Major Shareholder Clifford Sosin Buys 16,106 Shares

Cardlytics Inc (NASDAQ:CDLX) major shareholder Clifford Sosin acquired 16,106 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was bought at an average cost of $37.34 per share, for a total transaction of $601,398.04. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Clifford Sosin also recently made the following trade(s):

  • On Monday, October 21st, Clifford Sosin purchased 28,123 shares of Cardlytics stock. The shares were acquired at an average cost of $37.45 per share, for a total transaction of $1,053,206.35.
  • On Wednesday, October 16th, Clifford Sosin purchased 9,490 shares of Cardlytics stock. The shares were acquired at an average cost of $37.95 per share, for a total transaction of $360,145.50.
  • On Monday, October 14th, Clifford Sosin purchased 68,252 shares of Cardlytics stock. The shares were acquired at an average cost of $38.85 per share, for a total transaction of $2,651,590.20.
  • On Monday, October 7th, Clifford Sosin purchased 40,000 shares of Cardlytics stock. The shares were acquired at an average cost of $35.38 per share, for a total transaction of $1,415,200.00.
  • On Wednesday, October 9th, Clifford Sosin purchased 73,578 shares of Cardlytics stock. The shares were acquired at an average cost of $34.78 per share, for a total transaction of $2,559,042.84.

CDLX stock opened at $37.19 on Friday. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79. Cardlytics Inc has a 12 month low of $9.80 and a 12 month high of $39.83. The firm has a market cap of $845.88 million, a P/E ratio of -17.38 and a beta of 1.49. The company’s 50-day moving average price is $35.68 and its two-hundred day moving average price is $27.59.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The firm had revenue of $48.73 million for the quarter, compared to analyst estimates of $43.77 million. During the same period last year, the firm earned ($0.21) EPS. The business’s quarterly revenue was up 37.0% compared to the same quarter last year. Equities analysts predict that Cardlytics Inc will post -1.08 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in CDLX. Marshall Wace LLP bought a new position in Cardlytics in the 1st quarter valued at about $336,000. FMR LLC increased its holdings in Cardlytics by 2.3% in the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after buying an additional 72,847 shares during the period. Gamco Investors INC. ET AL increased its holdings in Cardlytics by 2.6% in the 2nd quarter. Gamco Investors INC. ET AL now owns 15,850 shares of the company’s stock valued at $412,000 after buying an additional 400 shares during the period. Tygh Capital Management Inc. increased its holdings in Cardlytics by 17.1% in the 2nd quarter. Tygh Capital Management Inc. now owns 176,237 shares of the company’s stock valued at $4,579,000 after buying an additional 25,790 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Cardlytics by 177.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 199,301 shares of the company’s stock valued at $4,901,000 after buying an additional 127,596 shares during the period. 84.08% of the stock is currently owned by hedge funds and other institutional investors.

CDLX has been the topic of a number of recent research reports. JPMorgan Chase & Co. set a $43.00 price target on shares of Cardlytics and gave the stock a “buy” rating in a research report on Friday, August 9th. William Blair initiated coverage on shares of Cardlytics in a research report on Monday, July 1st. They set an “outperform” rating on the stock. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday. SunTrust Banks raised their price target on shares of Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Raymond James raised their price target on shares of Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Cardlytics currently has a consensus rating of “Buy” and an average price target of $34.86.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Why is the price-sales ratio important?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.